Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Boston Scientific to buy Symetis for $435 million

Boston Scientific Corporation has announced its acquisition of privately held structural heart company, Symetis SA for $435 million. This move to acquire Symetis closely follows its acquisition of the manufacturing assets of Neovasc, Inc. as Boston Scientific continues to invest in structural heart through intellectual property, R&D, and manufacturing capabilities. These acquisitions will consolidate Boston Scientific's position in structural heart globally.


M&A,mergers and acquisitions,structural heart,valvular heart disease,Acurate systems,Symetis,Boston Scientific